Kartosthera
Founded 2018 · 70 employees on LinkedIn · 2 known investors
Find your way into Kartosthera
Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.
Investors · 2
Founder mafia
2 people who came through Kartosthera went on to found or lead other companies.
Frequently asked questions
- What does Kartosthera do?
- Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.
- Who are Kartosthera's investors?
- Kartosthera's investors include OrbiMed, SR One Capital Management.